HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target

Johnson & Johnson (NYSE:JNJ) is included among the 14 High Growth Dividend Paying Stocks to Invest in Now.

HSBC Sees Healthcare Strength, Lifts Johnson & Johnson (JNJ) Price Target

On March 17, HSBC analyst Morten Herholdt raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $280 from $265. It reiterated a Buy rating on the shares. The firm pointed to the current macro environment, noting that uncertainty, rising geopolitical risks, and lower exposure to AI disruption could draw investors toward healthcare and support outperformance in the near term.

On March 18, Reuters reported that the US Food and Drug Administration approved Johnson & Johnson’s oral pill for psoriasis. The approval gives patients a more convenient treatment option for the chronic autoimmune condition, which causes itchy, scaly, and inflamed skin. The drug is approved for moderate-to-severe plaque psoriasis in adults and children aged 12 and older who weigh at least 40 kg. The company did not respond to Reuters’ request for comment on pricing and availability.

The oral treatment, branded as Icotyde, is the first of its kind. It is expected to help Johnson & Johnson expand its presence in the psoriasis market and compete with existing treatments such as Bristol Myers Squibb’s Sotyktu and AbbVie’s Skyrizi. Wall Street analysts have said Icotyde has “blockbuster potential” as a safe and effective oral option. They also noted that a once-daily pill could take share from injectable treatments like Skyrizi and the company’s own Tremfya.

Johnson & Johnson (NYSE:JNJ) operates across a broad range of healthcare products. Its business is organized into two segments: Innovative Medicine and MedTech.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading into 2026 and 14 Quality Stocks with Highest Dividends

Disclosure: None. Follow Insider Monkey on Google News.